Shanghai Fosun Pharma Announces Drug Registration Acceptance
Company Announcements

Shanghai Fosun Pharma Announces Drug Registration Acceptance

Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.

Shanghai Fosun Pharmaceutical has announced the acceptance of drug registration applications for two new chemical drugs developed by its subsidiaries. These drugs, Levofloxacin Injection and Cytarabine Injection, have been approved by the National Medical Products Administration, marking a significant step in the company’s pharmaceutical innovations. This development could potentially enhance Fosun Pharma’s market position and attract investor interest.

For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskFosun Pharma Gains Approval for New Drug
TipRanks HongKong Auto-Generated NewsdeskShanghai Fosun Pharmaceutical Releases Q3 2024 Report
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App